Industry: Life Sciences Region: Sweden Transaction Price: US $1million Transaction Method: Equity investment
Project Introduction:
Coma survivors of out-of-hospital cardiac arrest have a high risk of death or poor neurological function.
International bodies such as the European Committee on Hypothermia Resuscitation (ERC) and the American Heart Association (AHA) recommend hypothermia treatment. According to a survey by Boston MedTech Advisors (2016), more than 70% of hospitals in the United States already use medical cooling systems, and the trend is increasing. Last year, about 80,000 people who suffered cardiac arrest were treated for hypothermia.
The Swedish company offers a solution that includes hardware and software for hypothermia therapy, including two steps:
1: Use the company's proven safe and effective internal cooler. Use the device to cool the patient as early as possible in the field of discovery and to maintain this condition throughout the hospital. At the hospital, they are hooked up to the company's temperature management system to protect the nerve cells from an immune response to ischemia or treatment. The use of an internal cooler for early, safe and effective temperature management, especially in the ventricular fibrillation group, may provide neuroprotection to the brain.
Step 2: Easy and safe to manage temperature in the intensive care unit with the company's advanced temperature management system, the product is the next generation of precision surface cooling equipment that provides high flow heat exchange, enabling incredible heat exchange and precise temperature maintenance. The system is user-friendly and capable of active alerts or alarms based on patient monitoring data.
The company's products are now available in the United States, Europe and Asia.
Cooperation Intention:
The company hopes to seek strategic partners in the Chinese market to jointly develop the Chinese market.